Page 50 - GPD-4-1

Gene & Protein in Disease GPER1 in brain and heart diseases

doi: 10.3390/ijms24109011 doi: 10.1159/000478908
85. Moriyama M, Hashimoto A, Satoh H, et al. S-equol, a 97. Bourque M, Morissette M, Côté M, Soulet D, Di Paolo T.
major isoflavone from soybean, inhibits nitric oxide Implication of GPER1 in neuroprotection in a mouse model
production in lipopolysaccharide-stimulated rat astrocytes of Parkinson’s disease. Neurobiol Aging. 2013;34(3):887-901.
partially via the GPR30-mediated pathway. Int J Inflamm. doi: 10.1016/j.neurobiolaging.2012.05.022
2018;2018:8496973.
98. Côté M, Bourque M, Poirier AA, et al. GPER1-mediated
doi: 10.1155/2018/8496973
immunomodulation and neuroprotection in the myenteric
86. Kajta M, Rzemieniec J, Litwa E, et al. The key involvement plexus of a mouse model of Parkinson’s disease. Neurobiol
of estrogen receptor β and G-protein-coupled receptor 30 Dis. 2015;82:99-113.
in the neuroprotective action of daidzein. Neuroscience. doi: 10.1016/j.nbd.2015.05.017
2013;238:345-360.
99. Mendes-Oliveira J, Lopes Campos F, Videira RA,
doi: 10.1016/j.neuroscience.2013.02.005
Baltazar G. GPER activation is effective in protecting against
87. Valera E, Masliah E. Therapeutic approaches in inflammation-induced nigral dopaminergic loss and motor
Parkinson’s disease and related disorders. J Neurochem. function impairment. Brain Behav Immun. 2017;64:296-307.
2016;139 Suppl 1(Suppl 1):346-352. doi: 10.1016/j.bbi.2017.04.016
doi: 10.1111/jnc.13529 100. Poirier AA, Côté M, Bourque M, et al. Differential
88. Morris HR, Spillantini MG, Sue CM, Williams-Gray CH. contribution of estrogen receptors to the intestinal
The pathogenesis of Parkinson’s disease. Lancet. therapeutic effects of 17β-estradiol in a murine model of
2024;403(10423):293-304. Parkinson’s disease. Brain Res Bull. 2022;187:85-97.
doi: 10.1016/S0140-6736(23)01478-2 doi: 10.1016/j.brainresbull.2022.06.019
89. Cherian A, Divya KP, Vijayaraghavan A. Parkinson’s 101. Sergi CM. Epigallocatechin gallate for Parkinson’s disease.
disease - genetic cause. Curr Opin Neurol. 2023;36(4):292-301. Clin Exp Pharmacol Physiol. 2022;49(10):1029-1041.
doi: 10.1097/WCO.0000000000001167 doi: 10.1111/1440-1681.13691
90. Russillo MC, Andreozzi V, Erro R, et al. Sex differences 102. Du ZR, Gu Y, Xie XM, et al. GPER and IGF-1R mediate
in Parkinson’s disease: From bench to bedside. Brain Sci. the anti-inflammatory effect of genistein against
2022;12(7):917. lipopolysaccharide (LPS)-induced nigrostriatal injury in
rats. J Steroid Biochem Mol Biol. 2021;214:105989.
doi: 10.3390/brainsci12070917
doi: 10.1016/j.jsbmb.2021.105989
91. Patel R, Kompoliti K. Sex and gender differences in
Parkinson’s disease. Neurol Clin. 2023;41(2):371-379. 103. Chavda VP, Chaudhari AZ, Balar PC, Gholap A,
Vora LK. Phytoestrogens: Chemistry, potential health
doi: 10.1016/j.ncl.2022.12.001
benefits, and their medicinal importance. Phytother Res.
92. Petrovska S, Dejanova B, Jurisic V. Estrogens: Mechanisms of 2024;38(6):3060-3079.
neuroprotective effects. J Physiol Biochem. 2012;68(3):455-460.
doi: 10.1002/ptr.8196
doi: 10.1007/s13105-012-0159-x
104. Calatayud E, Marcén-Román Y, Rodríguez-Roca B,
93. Simpkins JW, Singh M, Brock C, Etgen AM. Neuroprotection Salavera C, Gasch-Gallen A, Gómez-Soria I. Sex differences
and estrogen receptors. Neuroendocrinology. 2021;96(2):119-130. on anxiety and depression in older adults and their relationship
doi: 10.1159/000338409 with cognitive impairment. Semergen. 2023;49(4):101923.
doi: 10.1016/j.semerg.2023.101923
94. Cersosimo MG, Benarroch EE. Estrogen actions in the
nervous system: Complexity and clinical implications. 105. Di Benedetto MG, Landi P, Mencacci C, Cattaneo A.
Neurology. 2015;85(3):263-273. Depression in women: Potential biological and sociocultural
factors driving the sex effect. Neuropsychobiology.
doi: 10.1212/WNL.0000000000001776
2024;83(1):2-16.
95. Reekes TH, Higginson CI, Ledbetter CR, Sathivadivel N,
Zweig RM, Disbrow EA. Sex specific cognitive differences in doi: 10.1159/000531588
Parkinson disease. NPJ Parkinsons Dis. 2020;6:7. 106. Bromet E, Andrade LH, Hwang I, et al. Cross-national
epidemiology of DSM-IV major depressive episode. BMC
doi: 10.1038/s41531-020-0109-1
Med. 2011;9:90.
96. Guan J, Yang B, Fan Y, Zhang J. GPER Agonist G1 attenuates
neuroinflammation and dopaminergic neurodegeneration in doi: 10.1186/1741-7015-9-90
Parkinson disease. Neuroimmunomodulation. 2017;24(1):60-66. 107. Silveira PP, Pokhvisneva I, Howard DM, Meaney MJ.

Volume 4 Issue 1 (2025) 21 doi: 10.36922/gpd.4632